Annex 2 & Co - GMP Compliance for Biopharmaceuticals
Im Auftrag der ECA Academy

Annex 2 & Co - GMP Compliance for Biopharmaceuticals Im Auftrag der ECA Academy

Munich, Germany

Seminar Nr. 18022



ECA-Member: EUR 1590,--
Non ECA Member: EUR 1790,--
EU/GMP Inspectorates: EUR 895,--
APIC Member Discount: EUR 1690,--

Alle Preise zzgl. MwSt.

Rückfragen unter:
Tel.: 06221 / 84 44 0 E-Mail:


Dr Markus Fido, MFI Bio-Consulting
Dr Hiltrud Horn, Horn Pharmaceutical Consulting
Stephan Löw, CSL
Dr Daniel Müller, GMP Inspector, German Local Government,
Axel Schroeder, Concept Heidelberg


This Education Course concentrates on regulatory and practical requirements regarding biopharmaceutical production. From clinical phases to routine manufacturing practical examples and case studies will facilitate the implementation of GMP in your daily Business.

The course will treat the topics of routine inspection from regulatory bodies and customers, quality assurance and quality control as well as in laboratory and production.

Speakers from manufacturing, laboratory, consultancy and authority will show their expectations as well as their experiences in GMP implementation.


In defiance of all throwbacks in the last years, a progression of new approvals of biopharmaceuticals is expected.  Furthermore after the end of the protection of patents, biotechnical generics will be added.

Especially in the field of biotechnology you find particular challenges to fulfil the regulatory requirements on production and quality assurance. Industry and authorities have to face the new and expected changes in the regulatory Guidelines.


This course is advisable to people who
  • are involved in regulatory inspections,
  • work in quality units at biotech companies,
  • implement GMP in biotech production,
  • are responsible for GMP requirements pre-approval phases.


GMP Requirements Applying to Biotechnological Investigational Medicinal Products (IMPs of Clinical Phases I-III & APIs for use in IMPs)
  • EU regulations & guidances
  • Examples of national  regulations
  • State-of-the-art  manufacturing for clinical phases
GMP Guidelines for Biopharmaceuticals – a Brief Summary
  • Relevant international  regulations
  • European biotech guidances
  • Recent developments & possible impacts
Development of Biopharmaceuticals - GMP and Regulatory Aspects
  • GMP and regulatory documents
  • Ways to Success
  • Interaction with authorities (meetings/inspections)
Development, Qualification and Validation of Process Analytics for Biopharmaceuticals
  • Relevant guidelines
  • Phases of product development / testing requirements
  • Method portfolio/method development / method qualification / method validation
GMP Inspections in Biopharmaceutical Production
  • Inspections of biopharmaceutical companies
  • Focus & discussion points during inspections
  • Clean room classes for biotech facilities
  • Open vs. closed processing
  • Single vs. multi purpose equipment
  • Cell banking activities
  • Inspector’s experience, examples of observations
Case Study: Process Transfer from Development to Commercial Production
  • Key Aspects for EU and US
  • Difference between development and commercial production
GMP-conform Process Development and Validation (incl. Equipment Qualification)
  •  Introduction      
  •  Current initiatives in pharmaceutical development
  •  Biopharmaceuticals / Biosimilars / Biological
  1. Process
  2. Analytical Methods
  3. Equipment / Instruments and Facility
Quality Assurance for Biopharmaceuticals
  • Classical responsibilities of QA department
  • Allocation of responsibilities, training of staff
  • Dealing with suppliers & contractors
  • The world changes: Change management
  • Shit happens: Deviation management  & CAPA
  • Handling complaints & product  recalls
  • Paper, paper, paper: documentation works: SOPs, MBR, PQR & management report
  • Surveillance of qualification & validation, calibration and  maintenance
  • Self inspections & auditing
Bioanalytics for Clinical Trials – Method/Process Development and Validation for Phase I – III Studies
  •  Definitions of terms (ICH, Q’s)
  •  Process development & quality by design
  •  Early clinical phase
  •  Late clinical Phase
  •  Post approval
State-of-the-art Biotechnological Manufacture (Bacteria, Yeast, Mammalian Cells) and Cell Banking Activities - Part 1
  • Reasons for cell banking
  • Where does GMP start
  • Characterization of cell banks
  • Storage of cell banks
State-of-the-art Biotechnological Manufacture (Bacteria, Yeast, Mammalian Cells) and Cell Banking Activities - Part 2
  • Overview of a typical biotech process
  • Requirements on production areas, raw materials and equipment
  • Specialities on biotech products
  • Fill and finish
Case Studies Hygienic GMP Deviations
  • Examples of pitfalls
  • Chemical interactions
  • Human errors
  • Incorrect use
Prevention of  Cross Contamination: Dedicated Manufacturing or Cleaning Validation?
  • Requirements of Chapter 3 and 5 and Annex 2
  • Decision with consequences: multipurpose equipment or disposables
  • Dirt or product: zhe perspective defines  contamination
  • Ways to remove contaminants: cleaning procedures and their testing
  • Risk-based approach: Crucial element of the validation programme


GMP Seminare nach Thema

Cookies helfen uns bei der Bereitstellung unserer Dienste. Durch die Nutzung unserer Dienste erklären Sie sich damit einverstanden, dass wir Cookies setzen. Weitere Informationen